According to the official website of the State Medical Insurance Bureau, in order to further improve the level of medication protection for the insured, in accordance with the Interim Measures for the Administration of Medicines for Basic Medical Insurance and the Requirements of the Work Program for Adjustment of the National Drug Catalogs for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance for the Year of 2023, the State Medical Insurance Bureau and the Ministry of Human Resources and Social Security have organized to adjust and formulate the "Drug Catalog (2023)" for the National Drug Catalog (2023)", which was officially implemented from January 1, 2024 onwards.

This catalog includes human albumin, IVIG (intravenous human immunoglobulin), human fibrinogen, human plasminogen complex, human coagulation factor VIII, human coagulation factor IX, human immunoglobulin, tetanus human immunoglobulin, human rabies immunoglobulin, and recombinant human coagulation factor VIIa, recombinant human coagulation factor VIII, and recombinant human coagulation factor IX.

The catalog removes restrictions on two of the more widely used coagulation factor-based blood products (human fibrinogen and human plasminogen complex): human plasminogen complex is removed from the new 2023 edition of the catalog in the 2022 edition, which "is limited to surgical hemorrhage and hemorrhage due to liver disease, hemophilia B, and or hemophilia with inhibitors of coagulation factor VIII "In the new 2023 version, the limited scope of payment for human fibrinogen is eliminated in the new 2022 version, "limited to hemorrhage due to active bleeding from hypofibrinogenemia".

https://mp.weixin.qq.com/s/LMCqmAfacEPppYBsZZJ1Vw